Scientific programme highlights

posted on


The 21st International AIDS Conference (AIDS 2016) will offer a best-in-class programme of over 500 conference activities and sessions driven by top science and research discoveries. Here is a first glimpse of some of the scientific highlights:

HIV Vaccine & Functional Cure: Continuing Momentum

  • Cutting-edge research on gene-editing to help eradicate HIV
  • Novel discoveries on latently infected HIV cells, including how frequently cells are reactivated and how long they survive
  • New approaches to reduce the HIV viral reservoir and restore CD8+ T-cell function

Findings from Prevention Interventions and Trials

  • State of the HIV epidemic among women, including a 15-year trend analysis of the HIV gender gap between adolescent girls and boys in sub-Saharan Africa, as well as insights into HIV vulnerability of young women in inter-generational relationships 
  • Qualitative analyses of landmark HIV prevention trials for women shedding new light on adherence    
  • Insights on men who have sex with men (MSM) prevention issues, including new data on risk associated to online sex-seeking behaviours as well as mental health issues for MSM 
  • Cost-effectiveness of harm reduction interventions for people who inject drugs, as well as innovative approaches to increase their adherence to HIV treatment

Implementation and Progress

  • Analysis of countries’ capacities to report diagnosis, treatment and viral suppression data, and implications for tracking global progress towards achieving the 90-90-90 treatment goals
  • Progress and challenges in scaling up viral load testing in resource-limited settings
  • Optimal treatment strategies from high-burden regions, with lessons learned in reaching targets across the continuum of care
  • Analysis of year-to-year and long-term trends in HIV research funding, and implications for future funding needs

PrEP: Fulfilling its Current & Future Potential

  • Innovative methods to increase PrEP uptake in clinics, through community-based service delivery and at home
  • Latest information on next generation PrEP options, including long-acting injectables 
  • New data to guide PrEP implementation, including cost-effectiveness analyses across low-, middle- and high-income countries
  • Key insights from several PrEP open-label extension and demonstration studies  

HIV Co-infections & Co-morbidities: Overcoming Remaining Challenges

  • Advances in viral hepatitis and HIV co-infection treatment
  • Innovative strategies to reduce HIV and tuberculosis co-infection, including prevention of TB drug resistance
  • New data on the impact of co-morbidities – such as cancers, and cardiovascular, renal, and bone diseases 
| Return